Friday, September 23, 2022 2:56:43 PM
Scripts for week ending September 16, 2022
Drug Industry TRx: +5.5% w/w; +7.1% y/y
Vascepa
TRx 64,464; +4.8% (+2,948) w/w; -21.5% y/y
NRx 29,796; +10.2% (+2,752) w/w; -19.7% y/y
Ref 34,668; +0.6% (+196) w/w; -22.9% y/y
Lovaza (Fake & Brand)
TRx 65,492; +9.1% (+5,450) w/w; +1.9% y/y
NRx 32,289; +14.3% (+4,046) w/w; +2.8% y/y
Ref 33,203; +4.4% (+1,404) w/w; +1.0% y/y
Fake Vascepa
TRx 40,043; +6.8% (+2,566) w/w; As % of total V: 38.3%
NRx 19,465; +12.9% (+2,225) w/w; As % of total V: 39.5%
Ref 20,578; +1.7% (+341) w/w; As % of total V: 37.2%
Fake Vascepa by Manufacturer
Hikma - TRx 14,367; (+917) w/w; Generic share 35.9%; Total V share 13.7%
Reddy - TRx 18,124; (+934) w/w; Generic share 45.3%; Total V share 17.3%
Apotex - TRx 7,552; (+715) w/w; Generic share 18.9%; Total V share 7.2%
Vascepa + Fake Vascepa
TRx 104,507; +5.6% (+5,514) w/w; +3.1% y/y
NRx 49,261; +11.2% (+4,977) w/w; +2.7% y/y
Ref 55,246; +1.0% (+537) w/w; +3.5% y/y
Drug Industry TRx: +5.5% w/w; +7.1% y/y
Vascepa
TRx 64,464; +4.8% (+2,948) w/w; -21.5% y/y
NRx 29,796; +10.2% (+2,752) w/w; -19.7% y/y
Ref 34,668; +0.6% (+196) w/w; -22.9% y/y
Lovaza (Fake & Brand)
TRx 65,492; +9.1% (+5,450) w/w; +1.9% y/y
NRx 32,289; +14.3% (+4,046) w/w; +2.8% y/y
Ref 33,203; +4.4% (+1,404) w/w; +1.0% y/y
Fake Vascepa
TRx 40,043; +6.8% (+2,566) w/w; As % of total V: 38.3%
NRx 19,465; +12.9% (+2,225) w/w; As % of total V: 39.5%
Ref 20,578; +1.7% (+341) w/w; As % of total V: 37.2%
Fake Vascepa by Manufacturer
Hikma - TRx 14,367; (+917) w/w; Generic share 35.9%; Total V share 13.7%
Reddy - TRx 18,124; (+934) w/w; Generic share 45.3%; Total V share 17.3%
Apotex - TRx 7,552; (+715) w/w; Generic share 18.9%; Total V share 7.2%
Vascepa + Fake Vascepa
TRx 104,507; +5.6% (+5,514) w/w; +3.1% y/y
NRx 49,261; +11.2% (+4,977) w/w; +2.7% y/y
Ref 55,246; +1.0% (+537) w/w; +3.5% y/y
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
